Sanifit's SNF472 meets in Phase II for rare vascular calcification syndrome

Laboratoris Sanifit S.L. (Palma de Mallorca, Spain) said IV SNF472 met the primary endpoint of improving wound healing from baseline to week 12 as measured by the Bates-Jensen Wound Assessment Tool (BWAT) in a single-arm Phase II trial to treat calciphylaxis. SNF472 also met the secondary endpoint of reducing pain. The company declined to disclose details.

The open-label, international trial enrolled about 15 hemodialysis patients with calciphylaxis, a rare and severe vascular calcification and thrombosis syndrome...